Login to Your Account

Clinic Roundup

Wednesday, June 27, 2012

• GTx Inc., of Memphis, Tenn., reported data from a Phase IIb study showing that enobosarm, a selective androgen-receptor modulator, may play a role in the management of cancer patients with muscle wasting by improving physical function. Of the 159 subjects randomized to the study, 103 had physical function assessed at both baseline and following 16 weeks of treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription